Table 1.
United States Federal Drug Authority (FDA) Approved Pharmaceutical Agents
| Drug | Company | Purpose | Approval Date |
|---|---|---|---|
| Zubsolv®. Zubsolv® (buprenorphine and naloxone) | Orexo AB | Treatment of opioid dependence | July 2013 |
| Vivitrol® extended release naltrexone | Alkermes | Prevention of relapse to opioid dependence | October 2010 |
| Vivitrol® Naltrexone | Alkermes | Treatment of alcohol dependence | April 2006 |
| CHANTIX® (varenicline) | Pfizer | Treatment of nicotine addiction | May 2006 |
| Acamprosate calcium | Campral | Treatment of alcoholism | 2004 |
| Suboxone® (buprenorphine/naloxone) Subutex® (buprenorphine) | Reckitt Benckiser | Treatment of opiate dependence | October 2002 |
| Nicoderm CQ ® Nicorette® | GlaxoSmithKline | For smoking cessation | May 1997 |
| Naltrexone Hydrochloride oral tablets | Dupont | Tablet form (50mg taken daily) for the treatment of alcoholism | 1994 |
| Antabuse® (disulfiram) | Odyssey Pharmaceuticals | Treatment of alcohol dependence | 1951 |
Notes: Febo M, Blum K, Badgaiyan RD, Perez PD, Colon-Perez LM, Thanos PK, et al. Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z. PLoS ONE. 2017; 12(4): e0174774. © 2017 Febo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.109